RxNews Recap for Friday 07.16.10 Print E-mail
By BioMedReports.com Staff   
Friday, 16 July 2010 18:24
Below is a list of the companies that made news in the healthcare sector on Friday, July 16, 2010.
Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.
AVI BioPharma, Inc. (NASDAQ: AVII) a developer of RNA-based drugs, today announced upcoming presentations on AVI-4658, the Company's exon skipping therapy for the treatment of Duchenne muscular dystrophy, at the XII International Congress on Neuromuscular Diseases taking place July 17-22, 2010 in Naples, Italy. 
Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Wednesday, July 21, 2010, at 4:00 PM EDT to discuss the Company's announced major collaboration and investment from the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents. 
Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony, led by Governor Martin O’Malley and Fuad El-Hibri, Emergent’s chairman and chief executive officer, to mark the formal opening of Emergent Manufacturing Operations Baltimore.
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has amended the exercise price of its Series A Warrants and Series B Warrant sold in June 2010 from $1.57 per share to $1.64 per share. 
Exact Sciences Corp. (Nasdaq:EXAS), a company focused on the early detection and prevention of colon cancer, is pleased to welcome Daniel J. Levangie, Lionel N. St rling and David A. Thompson to the company's board of directors.
Ferro Corporation (NYSE: FOE) announced today that it will conduct a conference call on Tuesday, July 27, at 10:00 a.m. Eastern Time to discuss financial results for the three months ended June 30, 2010 and update an outlook for 2010 financial performance.
GLG Life Tech Corporation (TSX:GLG)(NASDAQ: LGL)  the vertically-integrated leader in the agricultural and commercial development of high quality stevia, announces the signing of a five-year agreement with Grupo Azucarero Mexico for the marketing and distribution of GLG's stevia extract products in Mexico.
GTC Biotherapeutics, Inc. ("GTC", OTCBB: GTCB.OB) announced today that it has signed a definitive agreement whereby the Company has regained US commercialization rights to ATryn from Lundbeck, Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen Stock Exchange: LUN).
ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the official opening of a purpose-built clinical pharmacology unit within the Central Manchester University Hospitals Foundation Trust (CMFT) campus in Manchester, UK.
Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of B. Melina Cimler, Ph.D., as Vice President, Quality and Regulatory Affairs, reporting to Christian Henry, Senior Vice President, Chief Financial Officer and General Manager, Life Sciences.
Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its option and licensing arrangement with Cangene Corporation (TSX: CNJ) has expired.
Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on developing clean, sustainable solutions for plastics, chemicals and energy, announced today that it will be releasing its second quarter 2010 financial results after the market close on Wednesday, July 28, 2010.
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, today announced that the Company has received a fifth extension of its waiver agreement with its Bond holders, allowing debt restructuring discussions to progress.
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million.
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its third quarter of fiscal year 2010 ended May 31, 2010 (3QFY10).
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE:524715) announced that USFDA has granted approval for its Abbreviated N w Drug Application (ANDA) to market a generic version of Flomax®, tamsulosin capsules.
Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) will issue its second quarter 2010 earnings release before the market opens on July 29, 2010. 
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Fermentas International Inc.
Tianyin Pharmaceutical (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine and branded generics provides progress update on its Jiangchuan macrolide facility.
Warner Chilcott plc (Nasdaq: WCRX) announced today that it has received a communication from the U.S. Food & Drug Administration (FDA) related to its next generation Actonel® product (risedronate sodium) delayed-release tablets extending the Prescription Drug User Fee Act (PDUFA) date by three months to allow sufficient time to review additional information solicited by the FDA and previously provided by the Company. 
ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that per their normal timing they will report third quarter results before the market opens on July 29, 2010. 
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter